Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Stock Transactions
SEC Form 4
Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- Richard Steinhart, the CFO of BioXcel Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions involving common stock and restricted stock units (RSUs).
- On September 14, 2024, 521 shares were acquired through the vesting of RSUs.
- On September 15, 2024, 563 shares were acquired through the vesting of RSUs.
- On September 16, 2024, 356 shares were disposed of at a price of $0.6899 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- The CFO directly owns 6,204 shares of common stock following the reported transactions.
- The RSUs vest in installments, contingent upon continuous employment with BioXcel Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an insider, which is neutral in sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| December 14, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| March 14, 2022 | Date the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| March 15, 2023 | Date the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| September 14, 2024 | Transaction date for acquisition of 521 shares of common stock through RSU vesting. |
| September 15, 2024 | Transaction date for acquisition of 563 shares of common stock through RSU vesting. |
| September 16, 2024 | Transaction date for disposal of 356 shares of common stock at $0.6899 per share. |
| September 17, 2024 | Date of the report. |
Keywords
Form 4, BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Rule 10b5-1 Trading Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.